Advanced Accelerator Applications (NASDAQ: AAAP) is one of 19 publicly-traded companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it compare to its rivals? We will compare Advanced Accelerator Applications to related businesses based on the strength of its institutional ownership, analyst recommendations, profitability, dividends, valuation, risk and earnings.

Valuation and Earnings

This table compares Advanced Accelerator Applications and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Advanced Accelerator Applications $148.93 million -$20.10 million -76.28
Advanced Accelerator Applications Competitors $2.40 billion $905.93 million 1.01

Advanced Accelerator Applications’ rivals have higher revenue and earnings than Advanced Accelerator Applications. Advanced Accelerator Applications is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Advanced Accelerator Applications and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Advanced Accelerator Applications -33.83% -16.05% -11.18%
Advanced Accelerator Applications Competitors -538.85% -41.85% -24.81%

Insider & Institutional Ownership

37.5% of Advanced Accelerator Applications shares are owned by institutional investors. Comparatively, 66.4% of shares of all “Specialty & Advanced Pharmaceuticals” companies are owned by institutional investors. 10.0% of shares of all “Specialty & Advanced Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

Advanced Accelerator Applications has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Comparatively, Advanced Accelerator Applications’ rivals have a beta of 0.85, meaning that their average stock price is 15% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Advanced Accelerator Applications and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Advanced Accelerator Applications 0 1 4 0 2.80
Advanced Accelerator Applications Competitors 63 299 947 27 2.70

Advanced Accelerator Applications currently has a consensus price target of $56.50, indicating a potential downside of 15.83%. As a group, “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 20.84%. Given Advanced Accelerator Applications’ rivals higher possible upside, analysts clearly believe Advanced Accelerator Applications has less favorable growth aspects than its rivals.

About Advanced Accelerator Applications

Advanced Accelerator Applications S.A. is a radiopharmaceutical company. The Company develops, produces and commercializes molecular nuclear medicine (MNM), diagnostic and therapeutic products. MNM uses trace amounts of radioactive compounds to create functional images of organs and lesions and to treat diseases, such as cancer. The Company has a portfolio of nine diagnostic positron emission tomography (PET) and single-photon emission computed tomography (SPECT) products. PET and SPECT are imaging techniques in molecular nuclear diagnostics (MND) with applications in clinical oncology, cardiology, neurology and inflammatory/infectious diseases. Its commercial products include Gluscan/Gluscan 500/Barnascan, FluoroChol, MIBITEC/Adamibi, DOPAVIEW, Leukokit, Neurolite, SomaKit and NETSPOT. Additional MND product candidates include Annexin V-128, a SPECT product candidate for the imaging of apoptotic and necrotic lesions with potential applications in a range of indications.

Receive News & Stock Ratings for Advanced Accelerator Applications S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanced Accelerator Applications S.A. and related stocks with our FREE daily email newsletter.